Safer blood clot treatment with apixaban than with rivaroxaban, according to large venous thrombosis trial

Results expected to change clinical practice and bring peace of mind to patients

2026-03-11

(Press-News.org) The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications.

Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs. It is the third leading cause of cardiovascular death after heart attack and stroke and is the most common preventable cause of death in hospitalized patients.

Clinical guidelines currently recommend that patients recovering from venous thrombosis take an anticoagulant such as apixaban or rivaroxaban for three months to prevent further clots. While these drugs are effective in preventing blood clots, serious bleeding can be a side effect.

The COBRRA trial, led by researchers at The Ottawa Hospital in Canada, aimed to directly compare bleeding with apixaban and rivaroxaban in venous thrombosis patients. The trial enrolled 2,760 participants from 32 sites across Canada, Australia and Ireland.

Results highlight major difference in bleeding risk

Results showed that 7.1 per cent of participants who received rivaroxaban experienced clinically relevant bleeding after three months compared to 3.3 per cent of participants who received apixaban, representing more than double the risk of bleeding with rivaroxaban. There was no significant difference in the risk of recurrent blood clots.

“These results clearly show that apixaban is the safer option for treating venous thrombosis,” said lead author Dr. Lana Castellucci, senior scientist and thrombosis physician at The Ottawa Hospital and professor at the University of Ottawa. “This trial provides highly anticipated evidence for physicians and should bring real peace of mind to venous thrombosis patients, who often live with the dual fear of blood clot recurrence and bleeding.”

“This practice-changing trial and its findings exemplify the powerful impact of academically led, government-funded clinical research in addressing questions that truly matter to patients,” said senior author Dr. Marc Rodger, Physician-in-Chief at the McGill University Health Centre (MUHC), senior scientist at the Research Institute of the MUHC, and affiliate senior scientist at The Ottawa Hospital.

Dr. Vivien Chen, Thrombosis Lead Haematologist at Concord Hospital and professor of medicine at University of Sydney, highlighted the value of international participation.

“Because this was a real world, standard of care trial conducted across three countries, the findings have strong global relevance,” she said. “Patients in Australia, Canada and Ireland were treated according to routine clinical practice, making the findings broadly applicable to diverse health systems and patient populations.”

Significant impact for patients

Clinical trial participant Jonathan Love agrees that the results are important for patients. The retired Ottawa resident enrolled in the trial in January 2025 after being diagnosed with venous thrombosis.

“I went to the hospital emergency department because of swelling in one leg and after some scans, the doctors found a pretty significant blood clot in my leg, as well as multiple major clots in my lungs,” said Love. “I was worried of course, but I knew I was in good hands. My treatment was a success and it feels good to know that I played a small part in this study that will help many others.”

Funding and acknowledgements: The COBRRA trial was funded by the Canadian Institutes of Health Research and Medical Research Future Fund in Australia with in-kind support from Royal College of Surgeons in Ireland and the International Network of Venous Thromboembolism Clinical Research Networks. Core support was provided by the Ottawa Methods Centre. The pilot trial was funded by the CanVECTOR network.

The Ottawa Hospital (TOH) is one of Canada’s top learning and research hospitals where we are guided by our vision to provide the world-class and compassionate care we would all want for our loved ones. Our multi-campus hospital, affiliated with the University of Ottawa, is home to the Regional Trauma Centre and Cancer Centre, and to discoveries that are adopted globally. Backed by generous support from the community, we are focused on reshaping the future of health care to improve the health of our diverse population of patients from Eastern Ontario, Western Quebec, and Nunavut. For more information about research at The Ottawa Hospital, visit ohri.ca.

Media contact
Jenn Ganton
Executive Director, Communications and Public Relations
Ottawa Hospital Research Institute
613-614-5253
jganton@ohri.ca

END

ELSE PRESS RELEASES FROM THIS DATE:

Turning herbal waste into a powerful tool for cleaning heavy metal pollution

2026-03-11

A new study demonstrates that agricultural and medicinal plant residues can be transformed into a highly effective material for removing toxic heavy metals from contaminated water and soil while also improving crop productivity. Researchers developed a phosphorus-modified biochar derived from residues of Salvia miltiorrhiza, a widely used medicinal herb, and showed that the material can simultaneously immobilize harmful metals and enhance soil fertility. Heavy metal pollution, particularly from lead and cadmium, is a persistent environmental problem worldwide. These contaminants can accumulate in soils and water, enter the food chain, and pose ...

Immune ‘peacekeepers’ teach the body which foods are safe to eat

2026-03-11

Food allergies are serious and, for some, potentially deadly. And yet, despite decades of research into allergies and what causes them, very little is known about why the vast majority of people are able to tolerate foods that can sicken or even kill others. “We know a lot about what the immune system sees and does if a patient has an allergy, but we know very little about what happens when things go right,” said Elizabeth “Beth” Sattely, an associate professor of chemical engineering in ...

AAN issues guidance on the use of wearable devices

2026-03-11

EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, MARCH 11, 2026 AAN issues guidance on the use of wearable devices Article examines smart watches, fitness trackers and more for neurological care Highlights: The AAN has issued new guidance on wearable devices and digital apps as potential tools in neurological care, focusing on non-FDA cleared technology. Wearables can monitor physical activity, sleep, heart rate and other health factors. Some can detect conditions like atrial fibrillation. Others can monitor disease-specific symptoms like seizures and headaches. This guidance for neurologists says the technology has great potential ...

In former college athletes, more concussions associated with worse brain health

2026-03-11

EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, MARCH 11, 2026 In former college athletes, more concussions associated with worse brain health Athletes assessed within five years of college graduation Highlights: Former college athletes with three or more concussions had slightly worse physical, mental, behavioral and cognitive health five years after graduation compared to those with no concussions. The study included 3,910 former college athletes from 20 sports, nearly half of whom were women. A majority competed at NCAA Division 1 schools. Athletes were evaluated at the start of their college sports careers and again within five years of graduation. ...

Racial/ethnic disparities among people fatally shot by U.S. police vary across state lines

2026-03-11

In a new analysis, racial and ethnic disparities in fatal shootings of U.S. residents by police varied widely between states. Roland Neil of the RAND Corporation in California, U.S., and colleagues present these findings in the open-access journal PLOS One on March 11, 2026. In the U.S., police officers fatally shoot about 1,000 people every year. Overall, Black U.S. residents are about twice as likely to die by police shooting than Hispanic U.S. residents, and about three times as likely to die by police shooting than White U.S. residents. However, few studies have examined the extent to which these racial/ethnic disparities differ between different ...

US gender differences in poverty rates may be associated with the varying burden of childcare

2026-03-11

Gender differences in poverty rates in the United States may be associated with women’s differing circumstances — particularly the burden of dependent children — rather than inherent to gender itself, according to a new study published March 11, 2026 in the open-access journal PLOS One by Patti Fisher of Virginia Tech, U.S. Women in the United States face higher rates of poverty than men, and their access to economic resources and opportunities is more limited. While factors such as employment, education, and health status are known to influence poverty risk, it has been unclear whether men and women are affected differently by these factors, ...

3D-printed robotic rattlesnake triggers an avoidance response in zoo animals, especially species which share their distribution with rattlers in nature

2026-03-11

3D-printed robotic rattlesnake triggers an avoidance response in zoo animals, especially species which share their distribution with rattlers in nature Article URL: https://plos.io/4bdJMhx Article title: The multimodal display of rattlesnakes is a deterring signal that works best with sympatric species Author countries: U.S. Funding: The author(s) received no specific funding for this work. END ...

Simple ‘cocktail’ of amino acids dramatically boosts power of mRNA therapies and CRISPR gene editing

2026-03-11

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers are racing to use them to ferry therapeutic mRNA into cells for cancer therapies and treatments for inflammatory diseases, as well as delivering CRISPR constructs that can correct disease-causing gene mutations. But a stubborn problem has slowed progress on all of these fronts. For LNPs to work therapeutically, they must transfer their cargo into cells by fusing with cell membranes, and they ...

Johns Hopkins scientists engineer nanoparticles able to seek and destroy diseased immune cells

2026-03-11

**EMBARGOED UNTIL MARCH 11 AT 2 P.M. ET** Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can “educate” the immune system to find and destroy disease-causing cells throughout the body. The study, they say, advances the field of engineering immune cells within a patient’s own body to combat cancers and autoimmune diseases including lupus, among other conditions. Engineered immune cells have been successfully used to treat an array of blood cancers, using CAR-T cells, or chimeric antigen receptor T cells. The treatment ...

A hidden immune circuit in the uterus revealed: Findings shed light on preeclampsia and early pregnancy failure

2026-03-11

BIRMINGHAM, Ala. – Early pregnancy depends on a remarkable act of coordination. Before the placenta can nourish a growing fetus, the embryo must securely “land” and connect with the mother’s blood supply — a process guided by a specialized group of immune cells called uterine natural killer cells, or uNK cells. A new peer-reviewed study from the University of Alabama at Birmingham, supported by the National Institutes of Health and published today in Science Translational Medicine, has uncovered a critical role in successful pregnancies for an immune switch ...

LAST 30 PRESS RELEASES:

Vaccine gaps rooted in structural forces, not just personal choices: SFU study